{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:41:03Z","timestamp":1788903663420,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T00:00:00Z","timestamp":1691193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Haiyan Fund of Harbin Medical University Cancer Hospital","award":["JJMS2023-05"],"award-info":[{"award-number":["JJMS2023-05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The radiopharmaceutical [<jats:sup>18<\/jats:sup>F]AlF-NOTA-FAPI-04 presents a promising alternative to <jats:sup>68<\/jats:sup>\u00a0Ga-FAPI owing to its relatively longer half-life. This study aimed to evaluate the clinical usefulness of [<jats:sup>18<\/jats:sup>F]AlF-NOTA-FAPI-04 PET\/CT for the diagnosis of primary and metastatic lesions in various types of gastrointestinal system cancers, compared with <jats:sup>18<\/jats:sup>F-FDG PET\/CT.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Patients diagnosed with gastrointestinal system malignancies were prospectively enrolled. All patients underwent both <jats:sup>18<\/jats:sup>F-FDG and <jats:sup>18<\/jats:sup>F-FAPI-04 PET\/CT scans within one week, with 44 (73.3%) for cancer staging and 16 (26.7%) for tumor restaging. Diagnostic efficacy of the primary tumor, as well as the presence and number of lymph nodes and distant metastases, were assessed. Tumor uptake was quantified by the maximum standard uptake value (SUVmax).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>For detection of primary tumor, the diagnostic sensitivity of <jats:sup>18<\/jats:sup>F-FDG PET\/CT was 72.7%, while it was 97.7% for <jats:sup>18<\/jats:sup>F-FAPI-04 PET\/CT. Based on per-lymph node analysis, the sensitivity, specificity, and accuracy of <jats:sup>18<\/jats:sup>F-FAPI-04 PET\/CT in diagnosing metastatic lymph nodes were 91.89%, 92.00%, and 91.96%, respectively. These values were notably higher than those <jats:sup>18<\/jats:sup>F-FDG PET\/CT (79.72%, 81.33% and 80.80%, respectively). The <jats:sup>18<\/jats:sup>F-FAPI-04 PET\/CT surpassed <jats:sup>18<\/jats:sup>F-FDG PET\/CT in detecting suspected metastases in the brain (7 vs. 3), liver (39 vs. 20), bone (79 vs. 51), lung (11 vs. 4), and peritoneal carcinoma (48 vs. 22). Based on per-patient analysis, differential diagnostic accuracies (<jats:sup>18<\/jats:sup>F-FAPI-04 vs. <jats:sup>18<\/jats:sup>F-FDG PET\/CT) were observed in all patients (91.7% vs. 76.7%), the initial staging group (90.9% vs. 79.5%), and the re-staging group (93.8% vs. 68.7%). Additionally, <jats:sup>18<\/jats:sup>F-FAPI-04 PET\/CT revised final diagnosis in 31.7% of patients, contrasting with <jats:sup>18<\/jats:sup>F-FDG PET\/CT, and prompted changes in clinical management for 21.7% of the patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:sup>18<\/jats:sup>F-FAPI-04 PET\/CT outperforms <jats:sup>18<\/jats:sup>F-FDG PET\/CT in delineating the primary gastrointestinal tumors and detecting suspected metastatic lesions due to a higher target-to-background ratio (TBR). Moreover, <jats:sup>18<\/jats:sup>F-FAPI-04 PET\/CT could provide valuable guidance for tumor staging, thereby having a potential impact on patient management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-023-06351-9","type":"journal-article","created":{"date-parts":[[2023,8,5]],"date-time":"2023-08-05T06:01:30Z","timestamp":1691215290000},"page":"4051-4063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["[18F] AlF\u2011NOTA\u2011FAPI\u201104 PET\/CT as a promising tool for imaging fibroblast activation protein in gastrointestinal system cancers: a prospective investigation of comparative analysis with 18F-FDG"],"prefix":"10.1007","volume":"50","author":[{"given":"Liping","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengsong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8776-5812","authenticated-orcid":false,"given":"Kezheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,5]]},"reference":[{"key":"6351_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/0256-4947.75771","volume":"31","author":"A Almuhaideb","year":"2011","unstructured":"Almuhaideb A, Papathanasiou N, Bomanji J. 18F-FDG PET\/CT imaging in oncology. Ann Saudi Med. 2011;31:3\u201313. https:\/\/doi.org\/10.4103\/0256-4947.75771.","journal-title":"Ann Saudi Med"},{"key":"6351_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.rcl.2021.06.001","volume":"59","author":"BA Howard","year":"2021","unstructured":"Howard BA, Wong TZ. 18F-FDG-PET\/CT Imaging for Gastrointestinal Malignancies. Radiol Clin North Am. 2021;59:737\u201353. https:\/\/doi.org\/10.1016\/j.rcl.2021.06.001.","journal-title":"Radiol Clin North Am"},{"key":"6351_CR3","first-page":"1292","volume":"101","author":"H Kato","year":"2004","unstructured":"Kato H, Sohda M. Kuwano H [Diagnosis of gastrointestinal tract malignancies using positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG)]. Nihon Shokakibyo Gakkai Zasshi. 2004;101:1292\u2013301.","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"6351_CR4","doi-asserted-by":"publisher","first-page":"103729","DOI":"10.1016\/j.cellimm.2017.12.003","volume":"343","author":"Z Liao","year":"2019","unstructured":"Liao Z, Tan ZW, Zhu P, Tan NS. Cancer-associated fibroblasts in tumor microenvironment-Accomplices in tumor malignancy. Cell Immunol. 2019;343:103729. https:\/\/doi.org\/10.1016\/j.cellimm.2017.12.003.","journal-title":"Cell Immunol."},{"key":"6351_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, Debus J, Altmann A, Jager D, et al. A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. J Nucl Med. 2018;59:1423\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.210435.","journal-title":"J Nucl Med"},{"key":"6351_CR6","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1097\/RLU.0000000000004073","volume":"47","author":"TF Cermik","year":"2022","unstructured":"Cermik TF, Ergul N, Yilmaz B, Mercanoglu G. Tumor Imaging With 68Ga-DOTA-FAPI-04 PET\/CT: Comparison With 18F-FDG PET\/CT in 22 Different Cancer Types. Clin Nucl Med. 2022;47:e333\u20139. https:\/\/doi.org\/10.1097\/RLU.0000000000004073.","journal-title":"Clin Nucl Med"},{"key":"6351_CR7","doi-asserted-by":"publisher","first-page":"693640","DOI":"10.3389\/fonc.2021.693640","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J, et al. (68)Ga-FAPI-04 Versus (18)F-FDG PET\/CT in the Detection of Hepatocellular Carcinoma. Front Oncol. 2021;11:693640. https:\/\/doi.org\/10.3389\/fonc.2021.693640.","journal-title":"Front Oncol."},{"key":"6351_CR8","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s00259-022-05758-0","volume":"49","author":"Y Wei","year":"2022","unstructured":"Wei Y, Zheng J, Ma L, Liu X, Xu S, Wang S, et al. [(18)F]AlF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET\/CT imaging of various cancers. Eur J Nucl Med Mol Imaging. 2022;49:2761\u201373. https:\/\/doi.org\/10.1007\/s00259-022-05758-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6351_CR9","doi-asserted-by":"publisher","first-page":"3683","DOI":"10.1245\/s10434-017-6078-x","volume":"24","author":"H In","year":"2017","unstructured":"In H, Solsky I, Palis B, Langdon-Embry M, Ajani J, Sano T. Validation of the 8th Edition of the AJCC TNM Staging System for Gastric Cancer using the National Cancer Database. Ann Surg Oncol. 2017;24:3683\u201391. https:\/\/doi.org\/10.1245\/s10434-017-6078-x.","journal-title":"Ann Surg Oncol"},{"key":"6351_CR10","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","volume":"48","author":"X Shi","year":"2021","unstructured":"Shi X, Xing H, Yang X, Li F, Yao S, Congwei J, et al. Comparison of PET imaging of activated fibroblasts and 18F-FDG for diagnosis of primary hepatic tumors: a prospective pilot study. Eur J Nucl Med Mol Imaging. 2021;48:1593\u2013603. https:\/\/doi.org\/10.1007\/s00259-020-05070-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6351_CR11","doi-asserted-by":"publisher","first-page":"1087792","DOI":"10.3389\/fonc.2022.1087792","volume":"12","author":"X Lin","year":"2023","unstructured":"Lin X, Li Y, Wang S, Zhang Y, Chen X, Wei M, et al. Diagnostic value of [68Ga]Ga-FAPI-04 in patients with colorectal cancer in comparison with [18F]F-FDG PET\/CT. Front Oncol. 2023;12:1087792. https:\/\/doi.org\/10.3389\/fonc.2022.1087792.","journal-title":"Front Oncol"},{"key":"6351_CR12","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1007\/s00259-021-05576-w","volume":"49","author":"Y Pang","year":"2022","unstructured":"Pang Y, Zhao L, Shang Q, Meng T, Zhao L, Feng L, et al. Positron emission tomography and computed tomography with [68Ga]Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2022;49:1322\u201337. https:\/\/doi.org\/10.1007\/s00259-021-05576-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6351_CR13","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s00259-021-05494-x","volume":"49","author":"J Kuten","year":"2022","unstructured":"Kuten J, Levine C, Shamni O, Pelles S, Wolf I, Lahat G, et al. Head-to-head comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG PET\/CT in evaluating the extent of disease in gastric adenocarcinoma. Eur J Nucl Med Mol Imaging. 2022;49:743\u201350. https:\/\/doi.org\/10.1007\/s00259-021-05494-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6351_CR14","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1007\/s00259-021-05441-w","volume":"49","author":"D Jiang","year":"2022","unstructured":"Jiang D, Chen X, You Z, Wang H, Zhang X, Li X, et al. Comparison of [68Ga]Ga-FAPI-04 and [18F]-FDG for the detection of primary and metastatic lesions in patients with gastric cancer: a bicentric retrospective study. Eur J Nucl Med Mol Imaging. 2022;49:732\u201342. https:\/\/doi.org\/10.1007\/s00259-021-05441-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6351_CR15","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2967\/jnumed.119.237016","volume":"61","author":"SA Koerber","year":"2020","unstructured":"Koerber SA, Staudinger F, Kratochwil C, Adeberg S, Haefner MF, Ungerechts G, et al. The Role of 68Ga-FAPI PET\/CT for Patients with Malignancies of the Lower Gastrointestinal Tract: First Clinical Experience. J Nucl Med. 2020;61:1331\u20136. https:\/\/doi.org\/10.2967\/jnumed.119.237016.","journal-title":"J Nucl Med"},{"key":"6351_CR16","doi-asserted-by":"publisher","first-page":"6596702","DOI":"10.1155\/2022\/6596702","volume":"2022","author":"H Zhang","year":"2022","unstructured":"Zhang H, An J, Wu P, Zhang C, Zhao Y, Tan D, et al. The Application of [68Ga]-Labeled FAPI-04 PET\/CT for Targeting and Early Detection of Pancreatic Carcinoma in Patient-Derived Orthotopic Xenograft Models. Contrast Media Mol Imaging. 2022;2022:6596702. https:\/\/doi.org\/10.1155\/2022\/6596702.","journal-title":"Contrast Media Mol Imaging"},{"key":"6351_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.21037\/tgh.2017.01.10","volume":"2","author":"K Ott","year":"2017","unstructured":"Ott K, Blank S, Ruspi L, Bauer M, Sisic L, Schmidt T. Prognostic impact of nodal status and therapeutic implications. Transl Gastroenterol Hepatol. 2017;2:15. https:\/\/doi.org\/10.21037\/tgh.2017.01.10.","journal-title":"Transl Gastroenterol Hepatol"},{"key":"6351_CR18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/RLU.0000000000003561","volume":"46","author":"M Deng","year":"2021","unstructured":"Deng M, Chen Y, Cai L. Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in the Imaging of Pancreatic Cancer With Liver Metastases. Clin Nucl Med. 2021;46:589\u201391. https:\/\/doi.org\/10.1097\/RLU.0000000000003561.","journal-title":"Clin Nucl Med"},{"key":"6351_CR19","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1967\/s002449912553","volume":"26","author":"Y G\u00fczel","year":"2023","unstructured":"G\u00fczel Y, Kaplan \u0130. Comparison of 68GA-FAPI-04 PET\/CT and 18F-FDG PET\/CT findings in peritonitis carcinomatosa cases. Hell J Nucl Med. 2023;26:26\u201334. https:\/\/doi.org\/10.1967\/s002449912553.","journal-title":"Hell J Nucl Med"},{"key":"6351_CR20","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1007\/s00259-020-05146-6","volume":"48","author":"L Zhao","year":"2021","unstructured":"Zhao L, Pang Y, Luo Z, Fu K, Yang T, Zhao L, et al. Role of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in the evaluation of peritoneal carcinomatosis and comparison with [18F]-FDG PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48:1944\u201355. https:\/\/doi.org\/10.1007\/s00259-020-05146-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6351_CR21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/s0016-5107(96)70240-7","volume":"44","author":"CJ Lightdale","year":"1996","unstructured":"Lightdale CJ. Diagnosis, staging, and cure of early gastrointestinal cancer. Gastrointest Endosc. 1996;44:95\u20136. https:\/\/doi.org\/10.1016\/s0016-5107(96)70240-7.","journal-title":"Gastrointest Endosc"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-023-06351-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-023-06351-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T03:25:22Z","timestamp":1698463522000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-023-06351-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,5]]},"references-count":21,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["6351"],"URL":"https:\/\/doi.org\/10.1007\/s00259-023-06351-9","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,5]]},"assertion":[{"value":"6 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the Institutional Review Board and Ethical Committee of Harbin Medical University Cancer Hospital and individual consent for this retrospective analysis was waived.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was waived for this prospective study.\u00a0All patients provided their written informed consent to participate in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}